Neoadjuvant Chemoimmunotherapy in Early Triple-Negative Breast Cancer: A New Kid on the Block?

References

• Gong J , Chehrazi-RaffleA , ReddiS , SalgiaR. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J. Immunother. Cancer6(1), 8 (2018).
   PubMed Web of Science ®Google Scholar
• Yang Y . Cancer immunotherapy: harnessing the immune system to battle cancer. J. Clin. Invest.125(9), 3335–3337 (2015).
   PubMed Web of Science ®Google Scholar
• Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer12(4), 252–264 (2012).
   PubMed Web of Science ®Google Scholar
• Rizzo A , RicciAD. PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?Expert Opin. Investig. Drugs31(4), 415–423 (2022)
   PubMed Web of Science ®Google Scholar
• Alsaab HO , SauS , AlzhraniRet al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front. Pharmacol.8, 561 (2017).
   PubMed Web of Science ®Google Scholar
• Bergin ART , LoiS. Triple-negative breast cancer: recent treatment advances. F1000Res8, F1000 Faculty Rev-1342 (2019).
   PubMedGoogle Scholar
• da Silva JL , CardosoNunes NC , IzettiP , de MesquitaGG , de MeloAC. Triple negative breast cancer: a thorough review of biomarkers. Crit. Rev. Oncol. Hematol.145, 102855 (2020).
   PubMed Web of Science ®Google Scholar
• Burtness B , HarringtonKJ , GreilRet al. KEYNOTE-048 investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet394(10212), 1915–1928 (2020).
   Web of Science ®Google Scholar
• Kwapisz D . Pembrolizumab and atezolizumab in triple-negative breast cancer. Cancer Immunol. Immunother.70(3), 607–617 (2021).
   PubMed Web of Science ®Google Scholar
• Badve SS , Penault-LlorcaF , Reis-FilhoJSet al. Determining PD-L1 status in patients with triple-negative breast cancer: lessons learned from IMpassion130. J. Natl Cancer Inst.114(5), 664–675 (2021).
   Google Scholar
• Rugo HS , LoiS , AdamsSet al. PD-L1 immunohistochemistry assay comparison in atezolizumab plus nab-paclitaxel-treated advanced triple-negative breast cancer. J. Natl Cancer Inst.113(12), 1733–1743 (2021).
   PubMedGoogle Scholar
• Rozenblit M , HuangR , DanzigerNet al. Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. J. Immunother. Cancer8(2), e001558 (2020).
   PubMed Web of Science ®Google Scholar
• Keenan TE , TolaneySM. Role of immunotherapy in triple-negative breast cancer. J. Natl Compr. Canc. Netw.18(4), 479–489 (2020).
   PubMed Web of Science ®Google Scholar
• Topalian SL , TaubeJM , PardollDM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science367(6477), eaax0182 (2020).
   PubMed Web of Science ®Google Scholar
• Schmid P , CortesJ , PusztaiLet al. KEYNOTE-522 investigators. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med.382(9), 810–821 (2020).
   PubMed Web of Science ®Google Scholar
• Schmid P , CortesJ , DentRet al. KEYNOTE-522: phase 3 study of neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy, followed by adjuvant pembrolizumab versus placebo for early-stage triple-negative breast cancer. Ann. Oncol.32(9), P1198–P1200 (2021).
   Web of Science ®Google Scholar
• Li Y , XingL , LiFet al. Efficacy and safety of adding immune checkpoint inhibitors to neoadjuvant chemotherapy against triple-negative breast cancer: a meta-analysis of randomized controlled trials. Front. Oncol.11, 657634 (2021).
   PubMedGoogle Scholar
• Mittendorf EA , ZhangH , BarriosCHet al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet396(10257), 1090–1100 (2020).
   PubMed Web of Science ®Google Scholar
• Bartsch R . SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer. Memo14(3), 247–251 (2021).
   PubMedGoogle Scholar
• Loibl S , UntchM , BurchardiNet al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNUEVO study. Ann. Oncol.30(8), 1279–1288 (2019).
   PubMed Web of Science ®Google Scholar
• Fountzila E , IgnatiadisM. Neoadjuvant immunotherapy in breast cancer: a paradigm shift?Ecancermedicalscience14, 1147 (2020).
   PubMed Web of Science ®Google Scholar
• Rizzo A , RicciAD , LanotteLet al. Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects. Expert Opin. Investig. Drugs doi:10.1080/13543784.2022.2009456 (2021) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Loi S , MichielsS , AdamsSet al. The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. Ann. Oncol.32(10), 1236–1244 (2021).
   PubMed Web of Science ®Google Scholar
• Rizzo A , RicciAD. Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond. Expert Opin. Investig. Drugs1–7 (2021).
   Web of Science ®Google Scholar
• Gianni L , HuangCS , EgleDet al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann. Oncol.33(5), 534–543 (2022).
   PubMed Web of Science ®Google Scholar
• Nanda R , LiuMC , YauCet al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol.6(5), 676–684 (2020).
   PubMed Web of Science ®Google Scholar
• Saini KS , PunieK , TwelvesCet al. Antibody–drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. Expert Opin. Biol. Ther.21(7), 945–962 (2021).
   PubMed Web of Science ®Google Scholar
• Tarantino P , CortiC , SchmidPet al. Immunotherapy for early triple negative breast cancer: research agenda for the next decade. NPJ Breast Cancer8(1), 23 (2022).
   PubMed Web of Science ®Google Scholar